|
ExpreS2ion Biotech Holding is a clinical-stage biotechnology company developing active immunotherapies and biologic drug candidates based on its proprietary ExpreS2 protein expression platform. The company’s lead asset, ES2B-C001, is an active immunotherapy candidate targeting HER2-expressing cancers, currently in Phase I clinical development. The broader pipeline includes partnered infectious disease programs in malaria, influenza, and Nipah virus, developed with academic and consortium partners. The ExpreS2 platform utilizes insect cells to produce complex proteins for therapeutic and immunology-based applications. The company focuses on oncology and infectious disease areas, aiming to improve patient outcomes through novel immunotherapies. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Biotechnology | Homepage expres2ionbio.com |
| Sector Healthcare | IR page expres2ionbio.com | |
|
Tags
active immunotherapy, oncology, infectious diseases, protein expression, vaccines, her2, malaria, influenza, nipah virus, clinical-stage, ES2B-C001, ExpreS2
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | kr 2.924M |
| P/E | -0.23 |
| P/BV | 0.08 |
| P/S | 0.80 |
| P/OCF | -0.07 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -75.8% |
| ROI | -106.7% |
| ROIC | -93.1% |
| Profit margin | -1,043.3% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -56.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | 3.65M | 3.01M | 7.05M | 5.08M | 12.23M | 5.25M |
| Net profit | 0 | -36.038M | -91.401M | -118.605M | -43.925M | 0 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.